19 results on '"Kamat, A.M."'
Search Results
2. Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III.
3. A0739 - Challenging the paradigm of BCG unresponsive bladder cancer: Does additional BCG have an effect?
4. A0583 - Efficacy of intravesical nadofaragene firadenovec-vncg for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: 36-month follow-up from a phase 3 trial.
5. 718TiP KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guérin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)
6. A0863 - Urachal (U) and Non-Urachal (NU) Adenocarcinomas (adenoCA) of the bladder: A comparative Comprehensive Genomic Profiling (CGP) study.
7. A0743 - Impact of systemic therapy in clinical T1 small-cell neuroendocrine carcinoma of the bladder.
8. A0742 - The international bladder cancer group intermediate-risk non-muscle invasive bladder cancer (IBCG IR-NMIBC) scoring system predicts the need for intervention for patients on active surveillance.
9. A1004 - International opinions on grading of urothelial carcinoma: A survey among European Association of Urology and International Society of Urological Pathology members.
10. A0722 - Bacillus calmette-guerin vs immediate radical cystectomy in eau defined very high-risk non-muscle invasive bladder cancer patients.
11. A0611 - Implementing the Active Surveillance (AS) follow-up schedule for low-grade Non- Muscle-Invasive Bladder Cancer (NMIBC) tumors.
12. A0607 - T1 substaging is associated with worse oncological outcomes for patients treated with Bacillus Calmette-Guerin or immediate radical cystectomy.
13. A0605 - Association of age with non-muscle-invasive bladder cancer: A biological basis for epidemiological disparities?
14. A0151 - Management, surveillance patterns, and costs associated with low-grade Papillary (Ta) non-muscle invasive bladder cancer.
15. A0147 - The updated EAU prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin.
16. PCN62 DISEASE BURDEN ASSOCIATED WITH PROGRESSION IN PATIENTS WITH HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER RECEIVING BLADDER PRESERVING THERAPIES AFTER ADEQUATE BCG INDUCTION: A SEER-MEDICARE DATABASE STUDY.
17. PCN42 TREATMENT PATTERNS AND SURVIVAL AMONG PATIENTS WITH BCG UNRESPONSIVE HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER: AN ASSESSMENT OF THE SEER-MEDICARE DATA.
18. 433 EFFICACY AND SAFETY OF MYCOBACTERIAL CELL WALL DNA COMPLEX IN THE TREATMENT OF PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER AT HIGH RISK OF PROGRESSION AND WHO ARE REFRACTORY TO BCG
19. 323 INTERNATIONAL VALIDATION OF THE PROGNOSTIC VALUE OF LYMPHOVASCULAR INVASION IN RADICAL CYSTECTOMY PATIENTS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.